Solid Biosciences (SLDB) Short-term Investments (2017 - 2026)

Solid Biosciences has disclosed Short-term Investments across 10 years of filings, most recently posting $83.6 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $83.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $83.6 million (changed N/A YoY), and the FY2025 annual result was $128.0 million, changed N/A from the prior year.
• Short-term Investments came in at $83.6 million for Q1 2026 at Solid Biosciences, down from $128.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $174.8 million in Q3 2025 to a low of $237000.0 in Q2 2022.
• The 5-year median for Short-term Investments is $88.5 million (2024), against an average of $82.7 million.
• Across the five-year window, Short-term Investments soared 103641.11% in 2022 and sank 58.56% in 2023, its largest moves.
• Solid Biosciences' Short-term Investments stood at $58.3 million in 2022, then retreated by 14.94% to $49.6 million in 2023, then surged by 115.06% to $106.7 million in 2024, then advanced by 19.89% to $128.0 million in 2025, then tumbled by 34.68% to $83.6 million in 2026.
• The last three Short-term Investments figures came in at $83.6 million (Q1 2026), $128.0 million (Q4 2025), and $174.8 million (Q3 2025), per Business Quant data.